BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 38022620)

  • 1. Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma.
    Hu M; Liao X; Tao Y; Chen Y
    Front Immunol; 2023; 14():1285113. PubMed ID: 38022620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
    Hua L; Wakimoto H
    Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Phillips LM; Li S; Gumin J; Daou M; Ledbetter D; Yang J; Singh S; Parker Kerrigan BC; Hossain A; Yuan Y; Gomez-Manzano C; Fueyo J; Lang FF
    Neuro Oncol; 2021 Nov; 23(11):1911-1921. PubMed ID: 34059921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
    Zhang Q; Liu F
    Cell Death Dis; 2020 Jun; 11(6):485. PubMed ID: 32587256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy.
    Wu ZJ; Tang FR; Ma ZW; Peng XC; Xiang Y; Zhang Y; Kang J; Ji J; Liu XQ; Wang XW; Xin HW; Ren BX
    Hum Gene Ther; 2018 Feb; 29(2):204-222. PubMed ID: 29179583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses for treatment of malignant brain tumours.
    Rainov NG; Ren H
    Acta Neurochir Suppl; 2003; 88():113-23. PubMed ID: 14531569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
    Kostova Y; Mantwill K; Holm PS; Anton M
    Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
    Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
    Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
    Hervás-Corpión I; Alonso MM
    Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.
    Aghi M; Visted T; Depinho RA; Chiocca EA
    Oncogene; 2008 Jul; 27(30):4249-54. PubMed ID: 18345032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.